Skip to main content

Company announcement

ENCLONY Expands Presence in Highly Potent Pharmaceutical Manufacturing Market with OEB 5 Containment Technology for Tablet Inspection and Capsule Inspection

ENCLONY Supplies OEB 5 Containment Tablet and Capsule Inspection System to European Pharmaceutical Manufacturer FAREVA EXCELLA, Strengthening Inspection and Containment Technology for HPAPI Manufacturing

Seoul, South Korea, November 16, 2026 -- As the pharmaceutical industry expands its production of highly potent pharmaceuticals, including anticancer drugs and hormone-based medications, the importance of containment technology for protecting operators and preventing cross-contamination in pharmaceutical manufacturing facilities continues to grow. These pharmaceuticals may involve highly potent active pharmaceutical ingredients (HPAPIs).

In manufacturing environments handling highly potent pharmaceuticals, it is important not only to accurately inspect the quality of pharmaceutical products but also to prevent dust and fine particles generated during production from being released into the surrounding environment. Accordingly, pharmaceutical manufacturing equipment is increasingly required to provide high levels of containment performance, along with safe cleaning and maintenance capabilities.

ENCLONY, a specialist in automated pharmaceutical visual inspection and laser printing solutions, is expanding its containment inspection solutions by combining machine vision-based tablet inspection and capsule inspection technologies with advanced containment design to meet the requirements of these manufacturing environments.

ENCLONY recently supplied its advanced containment automated visual inspection system, the EV CI-TC (EV Series – Containment Tablet/Capsule Inspection Machine), to FAREVA EXCELLA GmbH & Co. KG, a global pharmaceutical company based in Europe. The equipment was designed and manufactured to reflect FAREVA EXCELLA's actual production environment and Customer Requirement Specification.

The Planet EV CI-TC is a containment inspection system designed to automatically perform tablet inspection and capsule inspection in manufacturing environments for highly potent pharmaceuticals, including anticancer drugs and hormone-based medications.

The system incorporates OEB 5 (Occupational Exposure Band 5) containment performance and an IP67-rated dustproof and waterproof design. These features help minimize the release of pharmaceutical dust and fine particles into the surrounding environment during inspection, supporting operator protection and the prevention of cross-contamination between products.

In manufacturing facilities handling highly potent pharmaceuticals, maintaining containment is important not only during inspection but also during cleaning and maintenance operations. In particular, pharmaceutical substances remaining inside the equipment after production or during product changeovers must be safely removed.

To address these requirements, ENCLONY's containment inspection system incorporates a Wash-In-Place (WIP) function. This enables the equipment's interior to be cleaned without opening the system, helping reduce the risk of operator exposure to pharmaceutical substances and preventing the spread of contamination during cleaning operations.

Through this project, ENCLONY has expanded the application of its existing automated visual inspection technology to manufacturing environments for highly potent pharmaceuticals. The company plans to use this supply project as a key reference for expanding its presence in the global containment market, including Europe.

Kyung Ho Lee, CEO of ENCLONY, said, "As the production of highly potent pharmaceuticals continues to expand, visual inspection equipment is increasingly required to provide not only inspection accuracy but also high levels of containment performance that protect operators and manufacturing environments. The FAREVA EXCELLA project represents an important example of applying ENCLONY's automated visual inspection technology to highly contained manufacturing environments."

He added, "We plan to continue advancing our containment inspection technologies to meet the diverse requirements of global pharmaceutical companies producing highly potent pharmaceuticals, including anticancer drugs and hormone-based medications, while expanding our related business in global markets."

ENCLONY develops and manufactures pharmaceutical automation solutions, including automated visual inspection systems for tablets and capsules, as well as integrated laser printing and inspection systems. The company is expanding the global supply of containment inspection solutions for highly potent pharmaceutical manufacturing.

About ENCLONY

ENCLONY Co., Ltd., founded in 2013 and headquartered in Seoul, South Korea, specializes in pharmaceutical automation and inspection technologies. The company develops and manufactures automated visual inspection systems for tablets and capsules, as well as integrated laser printing and inspection solutions. Its technologies include machine vision-based inspection systems and containment inspection equipment for pharmaceutical manufacturing environments. ENCLONY provides inspection and automation solutions to pharmaceutical manufacturers in global markets.

For more information: www.enclony.com

Contact Info:
Name: Young-Mi Cho
Email: Send Email
Organization: ENCLONY Co., Ltd.
Website: https://enclony.com

Release ID: 89209380

If there are any deficiencies, discrepancies, or concerns regarding the information presented in this press release, we kindly request that you promptly inform us by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team is committed to addressing any identified issues within 8 hours to guarantee the delivery of accurate and reliable content to our esteemed readers.

This announcement was published as provided by the company. The Asean Coverage editorial team did not write or edit it.

Latest stories

All latest